Privileged Structures Revisited

Overview

Journal Angew Chem Int Ed Engl

Specialty Chemistry

Date 2017 May 31

PMID 28558125

Citations 30

Authors

Petra Schneider

Gisbert Schneider

Affiliations

Soon will be listed here.

Abstract

Privileged structures inspire compound library design in medicinal chemistry. We performed a comprehensive analysis of 1.4 million bioactive compounds, with the aim of assessing the prevalence of certain molecular frameworks. We used the Shannon entropy formalism to quantify the promiscuity of the most frequently observed atom scaffolds across the annotated target families. This analysis revealed an apparent inverse relationship between hydrogen-bond-acceptor count of a scaffold and its potential promiscuity. The results further suggest that chemically easily accessible scaffolds can serve as templates for the generation of bespoke compound libraries with differing degrees of multiple target engagement, and heterocyclic, sp -rich frameworks are particularly suited for target-focused library design. The outcome of our study enables us to place some of the many narratives surrounding the concept of privileged structures into a critical context.

Citing Articles

Combining molecular design with semiempirical protein-ligand binding free energy calculation.

Iff M, Atz K, Isert C, Pachon-Angona I, Cotos L, Hilleke M RSC Adv. 2024; 14(50):37035-37044.

PMID: 39569121 PMC: 11577348. DOI: 10.1039/d4ra05422a.

A General and Scalable Method toward Enantioenriched C2-Substituted Azetidines Using Chiral -Butanesulfinamides.

Zelch D, Russo C, Ruud K, OReilly M J Org Chem. 2024; 89(20):15137-15144.

PMID: 39348268 PMC: 11494643. DOI: 10.1021/acs.joc.4c01908.

Dual Antitubercular and Antileishmanial Profiles of Quinoxaline Di--Oxides Containing an Amino Acidic Side Chain.

Gonzalez J, Dea-Ayuela M, Huck L, Orduna J, Bolas-Fernandez F, de la Cuesta E Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675447 PMC: 11054274. DOI: 10.3390/ph17040487.

Enhancing the Small-Scale Screenable Biological Space beyond Known Chemogenomics Libraries with Gray Chemical Matter─Compounds with Novel Mechanisms from High-Throughput Screening Profiles.

Thomas J, Shelton 4th C, Murphy J, Brittain S, Bray M, Aspesi P ACS Chem Biol. 2024; 19(4):938-952.

PMID: 38565185 PMC: 11040606. DOI: 10.1021/acschembio.3c00737.

Thiazole, Isatin and Phthalimide Derivatives Tested against Cancer Models: A Literature Review of the Last Six Years.

Pinto A, Nunes J, Severino Martins J, Leal A, Silva C, da Silva A Curr Med Chem. 2023; 31(20):2991-3032.

PMID: 37170994 DOI: 10.2174/0929867330666230426154055.

References

Alves F, Barreiro E, Fraga C . From nature to drug discovery: the indole scaffold as a 'privileged structure'. Mini Rev Med Chem. 2009; 9(7):782-93. DOI: 10.2174/138955709788452649. View

Kaur G, Kaur M, Silakari O . Benzimidazoles: an ideal privileged drug scaffold for the design of multitargeted anti-inflammatory ligands. Mini Rev Med Chem. 2014; 14(9):747-67. DOI: 10.2174/1389557514666140820120518. View

Berthet M, Cheviet T, Dujardin G, Parrot I, Martinez J . Isoxazolidine: A Privileged Scaffold for Organic and Medicinal Chemistry. Chem Rev. 2016; 116(24):15235-15283. DOI: 10.1021/acs.chemrev.6b00543. View

Song Y, Chen W, Kang D, Zhang Q, Zhan P, Liu X . "Old friends in new guise": exploiting privileged structures for scaffold re-evolution/refining. Comb Chem High Throughput Screen. 2014; 17(6):536-53. DOI: 10.2174/1386207317666140122101631. View

Abagyan R, Kufareva I . The flexible pocketome engine for structural chemogenomics. Methods Mol Biol. 2009; 575:249-79. PMC: 2975493. DOI: 10.1007/978-1-60761-274-2_11. View

Dahlin J, Walters M . The essential roles of chemistry in high-throughput screening triage. Future Med Chem. 2014; 6(11):1265-90. PMC: 4465542. DOI: 10.4155/fmc.14.60. View

Weisel M, Kriegl J, Schneider G . Architectural repertoire of ligand-binding pockets on protein surfaces. Chembiochem. 2010; 11(4):556-63. DOI: 10.1002/cbic.200900604. View

Bajorath J . Analyzing Promiscuity at the Level of Active Compounds and Targets. Mol Inform. 2016; 35(11-12):583-587. DOI: 10.1002/minf.201600030. View

Glinca S, Klebe G . Cavities tell more than sequences: exploring functional relationships of proteases via binding pockets. J Chem Inf Model. 2013; 53(8):2082-92. DOI: 10.1021/ci300550a. View

10.

Walters W, Namchuk M . Designing screens: how to make your hits a hit. Nat Rev Drug Discov. 2003; 2(4):259-66. DOI: 10.1038/nrd1063. View

11.

Muller G, Berkenbosch T, Benningshof J, Stumpfe D, Bajorath J . Charting Biologically Relevant Spirocyclic Compound Space. Chemistry. 2016; 23(3):703-710. DOI: 10.1002/chem.201604714. View

12.

Seidler J, McGovern S, Doman T, Shoichet B . Identification and prediction of promiscuous aggregating inhibitors among known drugs. J Med Chem. 2003; 46(21):4477-86. DOI: 10.1021/jm030191r. View

13.

Irwin J, Duan D, Torosyan H, Doak A, Ziebart K, Sterling T . An Aggregation Advisor for Ligand Discovery. J Med Chem. 2015; 58(17):7076-87. PMC: 4646424. DOI: 10.1021/acs.jmedchem.5b01105. View

14.

Pihan E, Colliandre L, Guichou J, Douguet D . e-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design. Bioinformatics. 2012; 28(11):1540-1. DOI: 10.1093/bioinformatics/bts186. View

15.

Papadatos G, Gaulton A, Hersey A, Overington J . Activity, assay and target data curation and quality in the ChEMBL database. J Comput Aided Mol Des. 2015; 29(9):885-96. PMC: 4607714. DOI: 10.1007/s10822-015-9860-5. View

16.

Hu Y, Wassermann A, Lounkine E, Bajorath J . Systematic analysis of public domain compound potency data identifies selective molecular scaffolds across druggable target families. J Med Chem. 2009; 53(2):752-8. DOI: 10.1021/jm9014229. View

17.

Yan B, Xue M, Xiong B, Liu K, Hu D, Shen J . ScafBank: a public comprehensive Scaffold database to support molecular hopping. Acta Pharmacol Sin. 2009; 30(2):251-8. PMC: 4002465. DOI: 10.1038/aps.2008.22. View

18.

Marinozzi M, Marcelli G, Carotti A . N-Aryl-5-aminopyrazole: a versatile architecture in medicinal chemistry. Mini Rev Med Chem. 2015; 15(4):272-99. DOI: 10.2174/1389557515666150312154536. View

19.

Polanski J, Kurczyk A, Bak A, Musiol R . Privileged structures - dream or reality: preferential organization of azanaphthalene scaffold. Curr Med Chem. 2012; 19(13):1921-45. DOI: 10.2174/092986712800167356. View

20.

Roche O, Schneider P, Zuegge J, Guba W, Kansy M, Alanine A . Development of a virtual screening method for identification of "frequent hitters" in compound libraries. J Med Chem. 2002; 45(1):137-42. DOI: 10.1021/jm010934d. View